Concentration controlled therapy

International Congress Series

Volumn 1220, Issue C, 2001, Pages 135-144

  Holford, Nicholas H G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Between subject variability; Safe and effective variability; Target concentration strategy; Therapeutic drug monitoring; Within subject variability

Indexed keywords

EID: 3142553786     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00293-X     Document Type: Article

References (30)

1. Levy, G, Kinetics of pharmacologic effects. Clinical Pharmacology and Therapeutics 7 (1966), 362-372.
2. Holford, N.H.G, Sheiner, L.B, Understanding the dose–effect relationship: clinical application of pharmacokinetic–pharmacodynamic models. Clinical Pharmacokinetics 6 (1981), 429-453.
3. Holford, N.H.G, Physiological alternatives to the effect compartment model. D'Argenio, D.Z, (eds.) Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, 1991, Plenum, New York, 55-68.
4. Van Boxtel, C, Holford, N, Danhof, M, Vivo Study of Drug Action, 1992, Elsevier, Amsterdam.
5. Jusko, W.J, Ko, H.C, Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clinical Pharmacology and Therapeutics 56:4 (1994), 406-419.
6. Holford, N, Ludden, T, Time course of drug effect. Welling, P, Balant, L, (eds.) Handbook of Experimental Pharmacology, Chap. 11, 1994, Springer-Verlag, Heidelberg.
7. Sanathanan, L.P, Peck, C, Temple, R, Lieberman, R, Pledger, G, Randomization, PK-controlled dosing, and titration: an integrated approach for designing clinical trials. Drug Information Journal 25 (1991), 425-431.
8. Levy, G, Ebling, W.F, Concentration- and effect-controlled clinical trials with sparse data. Clinical Pharmacology and Therapeutics 56 (1994), 1-8.
9. Burton, M, Vasko, M, Brater, D, Comparison of drug dosing methods. Clinical Pharmacokinetics 10 (1985), 1-37.
10. Jelliffe, R, Schumitzky, A, Bayard, D, Milman, M, Van Guilder, M, Wang, X, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, bayesian feedback and individualised target goals. Clinical Pharmacokinetics 34 (1998), 57-77.
11. Holford, N.H.G, Black, P, Couch, R, Kennedy, J, Briant, R, Theophylline target concentration in severe airways obstruction—10 or 20 mg/l?. Clinical Pharmacokinetics 25:6 (1993), 495-505.
12. Evans, W, Relling, M, Rodman, J, Crom, W, Boyett, J, Pui, C, Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New England Journal of Medicine 338 (1998), 499-505.
13. Holford, N, Tett, S, Therapeutic drug monitoring. Speight, T.H.N, Holford, N, (eds.) Avery's Drug Treatment, 4th edn., 1997, Adis Intl, Auckland.
14. Holford, N, Target concentration intervention: beyond Y2K. British Journal of Clinical Pharmacology 48 (1999), 9-13.
15. Holford, N, A size standard for pharmacokinetics. Clinical Pharmacokinetics 30 (1996), 329-332.
16. West, G.B, Brown, J.H, Enquist, B.J, A general model for the origin of allometric scaling laws in biologi. Science 276 (1997), 122-126.
17. West, G.B, Brown, J.H, Enquist, B.J, The fourth dimension of life: fractal geometry and allometric scaling of organisms [see comments]. Science 284:5420 (1999), 1677-1679.
18. Sheiner, L, Tozer, T, Clinical pharmacokinetics: the use of plasma concentrations of drugs. Melmon, K, Morelli, H, (eds.) Clinical Pharmacology: Basic Principles of Therapeutics, 1978, Macmillan, New York, 71-109.
19. Whiting, B, Variability and control strategies in quantitative therapeutics. Melmon, K, Morrelli, H, (eds.) Clinical Pharmacology, 1992, McGraw-Hill, New York, 965-976.
20. Sidhu, J, Ashton, M, Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45 (1998), 347-354.
21. Karlsson, M.O, Sheiner, L.B, The importance of modeling interoccasion variability in population pharmacokinetic analyses. Journal of Pharmacokinetics and Biopharmaceutics 21:6 (1993), 735-750.
22. Lunn, D, Aarons, L, Markov Chain Monte Carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Applied Statistics 46 (1997), 73-91.
23. Bruno, R, Vivier, N, Libouix, A.L, Powe, L, Delumeau, J, Population pharmacokinetics of riluzole in patients with amuyotrophic lateral sclerosis. GR GR Clinical Pharmacology and Therapeutics 62 (1997), 518-526.
24. Wade, J, Sambol, N, Felodipine population dose–response and concentration–response relationships in patients with essential hypertension. Clinical Pharmacology and Therapeutics 57 (1995), 569-581.
25. Frame, B, Facca, B, Nicolau, D, Treisenberg, S, Population pharmacokinetics of continuous infusion ceftazidime. Clinical Pharmacokinetics 37 (1999), 343-350.
26. Jonsson, E, Wade, J, Karlsson, M, Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetic and Biopharmaceutics 24 (1996), 245-263.
27. Karlsson, M, Jonsson, E, Wilste, C, Wade, J, Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. Journal of Pharmacokinetic and Biopharmaceutics 26 (1998), 207-246.
28. Bouillon, T, Meineke, I, Port, R, Hildebrandt, R, Günther, K, Gundert-Remy, U, Concentration–effect relationship of the positive chronotropic and hypokalaemic effects of fenoterol in healthy woimen of childbearing age. European Journal on Clinical Pharmacology 51 (1996), 153-160.
29. Upton, R, Thiercelin, J, Moore, J, Riegelman, S, A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies. Journal of Pharmacokinetics and Biopharmaceutics 10 (1982), 135-146.
30. Sanathanan, L.P, Peck, C, Temple, R, Lieberman, R, Pledger, G, Randomization, PK-controlled dosing, and titration: An integrated approach for designing clinical trials. Drug Information Journal 25 (1991), 425-431.